Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonefpeglutide
- Development stage
- Phase 2
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Sonefpeglutide is a long-acting glucagon-like peptide 2 (GLP-2) analog developed by Hanmi Pharmaceutical Company Limited. It is a recombinant fusion protein chemically conjugated with the constant region of human immunoglobulin G4 (hIgG4 Fc) via a polyethylene glycol linker, utilizing Hanmi's proprietary Lapscovery platform. This design aims to enhance efficacy and enable once-monthly subcutaneous administration. Sonefpeglutide acts as a GLP-2 receptor agonist, promoting intestinal growth and absorption capacity. It is primarily being developed for the treatment of Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) and has received Orphan Drug Designation and Fast Track Designation from the FDA for this indication.
- Other names
- LAPS-GLP-2LAPS-GLP2LAPS-GLP 2
02
Targets
GLP2R (Glucagon-like peptide 2 receptor)
Beyond the preview
Go deeper on sonefpeglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonefpeglutide.